BioVib recorded approximately KRW 710 million in revenue from the United States during the first half of this year, re‑shaping its overseas sales structure that had previously been centered on China. This achievement is a result of two new businesses—“ECM Skin Booster” and “Piller”—which have become growth engines for the company.
A report released by research institute Belyu Pander on the 31st showed that BioVib’s North American offline network has contributed to this year’s revenue. The firm, founded in 2018, has grown into a medical aesthetic company and secured capital through its listing on KOSDAQ last year.
According to the first‑half annual report, BioVib’s revenue for the period was KRW 1.79 billion, an increase of 0.4% compared with the same period last year. Operating profit rose to KRW 530 million, a 17.2% rise, and operating margin reached 29.6%. In particular, sales from the U.S. have expanded significantly, now accounting for 39.5% of total sales.
In one article, “ECM Skin Booster” was highlighted as a product line that emphasizes skin tissue regeneration and renewal; its market size is estimated to grow from about KRW 990 million last year to KRW 1.10 billion this year, and KRW 2.00 billion in 2027.
The Piller business has been progressing overseas licensing, with “Corena Premium Piller Soft Molecule” having obtained domestic approval for a drug and proceeding with EU CE(MDR) and China NMPA as well. Researcher Junwoo Bin said, “U.S. sales expansion is occurring simultaneously in online and offline channels, improving practical stability,” underscoring the growth potential of these new businesses.